SAFETY AND TOLERABILITY OF IODIXANOL IN HEALTHY-VOLUNTEERS WITH REFERENCE TO 2 MONOMERIC X-RAY CONTRAST-MEDIA

被引:29
作者
JORGENSEN, NP
NOSSEN, JO
BORCH, KW
KRISTIANSEN, AB
KRISTOFFERSEN, DT
LUNDBY, B
THEODORSEN, L
机构
[1] Laboratory for Clinical Pharmacology, The Norwegian Radium Hospital, Oslo
[2] Nycomed AS, Oslo
[3] the Central Laboratory, The Norwegian Radium Hospital, Oslo
关键词
CONTRAST MEDIA; COMPARATIVE STUDY; COMPLICATION;
D O I
10.1016/0720-048X(92)90118-S
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The low osmolar, non-ionic X-ray contrast media have shown a lower frequency of adverse events than the older ionic ones. In this study changes in routine clinical-chemical parameters in blood and urine, vital signs and adverse events were recorded in six groups of 10 healthy male volunteers receiving either iodixanol, a new non-ionic, dimeric X-ray contrast medium for general vascular use, or one of the two non-ionic, monomeric contrast media iopentol and iopamidol. Minor decreases were observed in the values for haemoglobin, haematocrit and erythrocytes 5 min and 3 days after injection of iodixanol. A minor increase was seen in platelets and total protein after 3 days. A transient increase in serum osmolality was seen 5 min after the injections of iopentol and iopamidol. This was not seen in any iodixanol group. The level of thyrotropin showed an increase in all groups at 3 days. It was back to normal within 21 days. No changes of clinical importance were seen regarding blood pressure, heart rate or ECG in any volunteer. No severe adverse events were reported. All events were of short duration, and of mild or moderate intensity. The results, however, may indicate a lower frequency of adverse events/discomfort after the administration of the dimeric iodixanol than the 2 monomeric contrast media iopentol and iopamidol.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 13 条
  • [1] Nossen, Aakhus, Berg, Jorgensen, Andrew, Experience with iodixanol, a new nonionic dimeric contrast medium. Preliminary results from the human phase I study, Invest Radiol, 25, pp. S113-S114, (1990)
  • [2] Andrew, Dahlstrom, Sveen, Hvinden, Holager, Mowinckel, Renaa, Laulund, Intravascular studies with Iohexol (Omnipaque<sup>®</sup>). Results from the first 49 clinical trials, Eur J Radiol, 5, pp. 68-76, (1985)
  • [3] Dray, Winfield, Muhlertaler, Kirchner, Advantages of nonionic contrast agents in adult urography, Urology, 24, pp. 297-299, (1984)
  • [4] Katayama, Yamaguchi, Kozuka, Takashima, Seez, Matsuura, Adverse reactions to ionic and nonionic contrast media. A report from the Japanese committee on the safety of contrast media, Radiology, 175, pp. 621-628, (1990)
  • [5] Schrott, Behrends, Clauss, Kaufmann, Lehnert, Iohexol in excretory urography Results from the drug monitoring programme, Fortschr Med, 104, pp. 153-156, (1986)
  • [6] Wolf, Adult peripheral angiography. Results from four North American randomized clinical trials of ionic media versus iohexol, Acta Radiol, pp. 166-170, (1983)
  • [7] Svaland, Haider, Langseth-Manrique, Andrew, Hals, Human pharmacokinetics of iodixanol, Invest Radiol., 27, pp. 130-133, (1992)
  • [8] Jakobsen, Lundby, Kristoffersen, Borch, Hald, Berg, Renal function and delayed CT after injection of non-ionic monomeric and dimeric contrast media in healthy volunteers, Radiology, 182, pp. 419-424, (1992)
  • [9] Levorstad, Kolbenstvedt, Kolmannskog, Sommerfelt, Stormorken, Andrew, Sveen, Tolerability of iohexol after injection into healthy volunteers, Acta Radiol Diagn, 24, pp. 241-251, (1983)
  • [10] Gruters, I'Allemand, Klett, Helge, The problem of the influence of modern iodinated contrast media on thyroid metabolism in babies, Contrast media in pediatric radiology, pp. 87-93, (1985)